Takeda's Licensing Activities

Takeda's mission is to "strive toward better health for individuals and progress in medicine by developing superior pharmaceutical products." To deliver innovative new drugs longed for by patients, doctors, and medical service providers as early as possible, Takeda defines its alliance and licensing activities as reinforcement measures to complement its proprietary research and development pipelines.
To develop global licensing activities efficiently and dynamically, Takeda has established a system that allows quick actions and decision making by allocating alliance specialists in 3 key strategic regions, i.e., Japan, the United States, and Europe, under the Global Licensing & Business Development Department, an organization directly reported to our president.

Takeda also maintains the following as the basic concepts of its licensing activities to maximize the synergy from combinations of our superior points with those of our partners.

• 1. Respecting our partners' passion and visions.
• 2. Proposing creative schemes that will generate merits for both Takeda and our partners to keep "our mutual win-win situation."
• 3. Generous contribution, and commitment, by each of our related division and by our management team, leading to success in mutual alliances.

Profile of the license section

In this homepage, licensing activities of our company are described by itemizing them as follows.

1. Takeda as a world-class partner

The Takeda Group, which sells its 4 original international strategic products^[*] in major countries, is appreciated as a global alliance partner. Takeda cherishes its relationships of mutual trust with its partners and develops their ideas and/or compounds into global products by taking advantage of our original research and development and sales capabilities.

[*] Leuplin (generic name: leuprorelin acetate), a treatment for prostate cancer and endometriosis; Takepron (generic name: lansoprazole), a treatment for peptic ulcer; Blopress (generic name: candesartan cilexetil), an anti-hypertensive agent; and Actos (generic name: pioglitazone hydrochloride), an antidiabetic agent.

2. Therapeutic and Technology Areas of interest

We describe the therapeutic areas that Takeda places priority on, under the background of our wealth of knowledge and expertise, together with a challenging therapeutic area, into which Takeda plans to explore with joining the new market. It is also aggressively exploring unique drug-development technologies.

3. Recent achievement deals

This section describes the records of Takeda's successful alliances with various partners, ranging from global pharmaceutical companies to relatively smaller firms.

4. The Process

Takeda follows our alliance processes from the first contact to fulfill of the contract in a steady way, but with speedy steps.

5. Out Licensing

Takeda may also conduct the development and sales of our original compounds with expertized partners with excellent know-how to deliver them to the world as early as possible.

6. Licensing Contact

Inquiries about our licensing activities and information on ideas and compounds are accepted here.